Skip to main content

Researchers identify a molecule that halts and reverses neurodegeneration in Parkinson’s disease

25 Sep 18



Postdoctoral Fellow
Tel.+34 93 40 37127
Emeritus Professor
Tel.+34 93 40 37125


Communication Officer
Tel.+34 93 40 37255

The digital newspaper Público and other media have echoed a study headed by the Universitat Autònoma de Barcelona (UAB) and involving researchers from the Chemistry and Molecular Pharmacology Programme at IRB Barcelona that offers a promising advance towards a treatment for Parkinson’s disease,.

Published in the journal PNAS, the study has revealed that a small molecule, called SynuClean-D, disrupts the formation of amyloid fibers of alpha-synuclein—the process that triggers the development of Parkinson’s disease—and reverses the neurodegeneration that ensues.

Jesús Garcia, Salvador Guardiola, Ernest Giralt and Xavier Salvatella are among the authors of the paper, whose first authors are from the Instituto de Biotecnología y Biomedicina of the UAB. The collaboration has also involved researchers from the universities of Barcelona, Vic and Zaragoza, the University Medical Center of Göttingen (Germany), the Sorbonne University (France), the Max Planck Institute for Experimental Medicine (Germany), and Newcastle University (UK).

Link to Público: Researchers identify a molecule that halts and reverses neurodegeneration in Parkinson’s disease (Spanish)

About IRB Barcelona

Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 28 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).